January 26, 2022
This systematic review of the literature identified seven studies addressing ADHD and sexuality.
Sexual function
A Dutch study compared 136 persons with ADHD with two large surveys of the general Dutch population. They used both a self-report questionnaire, the Questionnaire for screening Sexual Dysfunction and a non-validated questionnaire especially constructed for the study. They found that males with ADHD reported a 50 percent higher rate of frequent masturbation than males in the general population. Both males and females were less than half as likely to be satisfied with their sex life. That was almost certainly linked to the fact that ADHD participants in the sample were less likely to be in a relationship.
A second study compared 79 ADHD participants with controls. Using a validated questionnaire, the Diagnostic Interview Schedule, to assess sexual function, they found a significant positive correlation between ADHD and the items "sex drive more than the average" and "recurrent thoughts about sex' by comparison with the control group.
A third study used two validated inventories “ the Derogates Sexual Functioning Inventory and the Social Sexual Orientation Inventory“ to assess sexual function among 27 young adult males. They found their sex drive to be higher than in the control group.
Another study, also with 27 ADHD patients, compared them with two other groups, one with fiber mitosis (benign connective tissue cancers), and the other with both ADHD and fibromatosis. They used the validated Life Satisfaction Questionnaire to assess sexual function and found that those with ADHD reported lower sex life satisfaction.
On the other hand, the only large study, with over 14,000 participants, using a non-validated questionnaire to assess sexual function, found negligible associations between ADHD and the number of sexual partners, the frequency of having sex with one's partner, and the frequency of masturbation.
Sexual dysfunctions
The Dutch study mentioned above, comparing 136 ADHD outpatients with two large surveys of the general Dutch population, used a validated self-report questionnaire, the Questionnaire for screening Sexual Dysfunctions, and a non-validated questionnaire, specially designed for the study, the Questionnaire for screening Sexual Problems. It found the rate of sexual dysfunction among both males and females with ADHD to be over twice the level in the general population. Men were four times as likely to report problems with orgasm, 50 percent more likely to report premature ejaculation, and over ten times as likely to report sexual aversion. Women were over three times as likely to report sexual excitement problems, over twice as likely to report problems with orgasm, and over three times as likely to report sexual aversion. No significant differences existed between patients treated with psychostimulants and those without such treatment.
A second study, which used a validated questionnaire to compare 79 ADHD participants with controls, found significant correlations between ADHD and aversion to sex for men but none for women.
On the other hand, a third study, comparing 32 subjects with ADHD with 293 controls, found no significant difference in the prevalence of sexual dysfunctions. It used clinical interviews to assess ADHD, and a non-validated questionnaire to assess sexual dysfunctions.
A fourth study took a very different approach. It compared 38 individuals with premature ejaculation to 27 controls. It found more than ten times the rate of ADHD symptoms among those with premature ejaculation than in the control group. Significantly, it measures premature ejaculation directly, with a stopwatch.
Conclusion
The authors concluded, "This article provides the first systematic review of sexual health among subjects with ADHD and shows that the quality of sexual health among subjects with ADHD seems poor," but acknowledged "several limitations to our review. There are only a few studies for the topics we reviewed. For many studies, the sample size was small. The methodology and measurement instruments differed, which created a potential bias."
Indeed, the study with the largest sample size found negligible associations between ADHD and sexual function, contradicting studies with small sample sizes.
Only four of the studies, all with small sample sizes, examined sexual dysfunctions. Two found strong associations with ADHD, one found none, and the fourth had mixed results.
This points to a compelling need for further research on ADHD and sexuality, with larger sample sizes.
Lorenzo Soldati, MD, Francesco Bianchi-Demicheli, MD, Pauline Schockaert, MAS, John Köhl, MAS, MylèneBolmont, Ph.D., Roland Hasler, Ph.D., and Nader Perroud, MD, “SexualFunction, Sexual Dysfunctions, and ADHD: A Systematic Literature Review,” Journal of Sexual Medicine(2020),https://doi.org/10.1016/j.jsxm.2020.03.019.
A 2021 consensus statement by an international group of scientists and clinicians (Bauer et al.) recommended that pregnant individuals “forego [acetaminophen] unless its use is medically indicated,” due to the potential risk of developmental disorders such as autism and attention-deficit/hyperactivity disorder (ADHD).
A mostly Swedish research team, collaborating with a U.S. researcher, nevertheless noted that previous studies have been limited by:
Sweden has a single-payer health insurance system that includes virtually its entire population, and national registers that enable tracking the health history of mothers and their children, including their children’s siblings.
The team used the Swedish registers to identify the roughly two-and-a-half million children born in Sweden from mid-1995 through 2019. They were also able to identify all siblings to be able to control for otherwise unmeasured familial and genetic confounding.
Almost 186,000 of these children were exposed to acetaminophen during pregnancy.
After adjusting for available known confounders, including (but not limited to) child sex and birthdate, mother’s age and medical history, use of any other painkillers, use of any psychoactive medications, country of birth, residential region, smoking status, highest household education, and disposable income, children exposed to acetaminophen during pregnancy were 7% more likely to be diagnosed with ADHD subsequently than those who were not exposed.
However, roughly the same results were found for other painkillers, including aspirin, non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, and antimigraine medication. High doses of acetaminophen did not produce any stronger association with subsequent ADHD than low dosage.
Moreover, when confining results to siblings – 8,526 children who were exposed versus 87,679 who were unexposed – the association between acetaminophen use during pregnancy and subsequent offspring ADHD vanished altogether (and, again, at every dose level). The associations similarly vanished with every other painkiller medication.
The Swedish team concluded, “Acetaminophen use during pregnancy was not associated with children’s risk of autism, ADHD, or intellectual disability in sibling control analyses. This suggests that associations observed in models without sibling control may have been attributable to confounding.”
Antipsychotic medications are used to treat a variety of psychiatric disorders, including schizophrenia, bipolar disorder, sleeping problems, major depression, and severe anxiety.
Untreated maternal mental illness is associated with poor health outcomes for both mothers and their offspring. On the other hand, one must guard against any potential direct harms of medications on development – including neurological development – of the fetus.
Because prenatal use of antipsychotics is infrequent, previous observational studies have suffered from small sample sizes that have not enabled precise and reliable assessment of risk. The clinical decision about whether to continue antipsychotic treatment in patients who become pregnant has therefore remained inconclusive.
In search of more reliable guidance, an international study team conducted a systematic search of the peer-reviewed medical literature to perform the first meta-analysis on this topic.
They evaluated study quality and only included studies rated “good” or better.
Identification of ADHD was determined by clinical diagnosis.
Meta-analysis of four studies encompassing over eight million participants found a slight association. Children exposed to maternal antipsychotics during pregnancy were 11% more likely to be diagnosed with ADHD subsequently.
But even in observational studies with millions of participants, such associations – especially when slight to begin with – could be due to unmeasured confounders.
The team therefore compared children with gestational exposure to siblings from the same mother who were not exposed, to address shared genetic and social factors at the family level.
Meta-analysis of two population-based sibling-matched studies with a combined total of over 4.6 million participants in Denmark, Norway, Sweden, Finland, Iceland, and Hong Kong found no significant association between gestational exposure to antipsychotic medications and subsequent diagnosis of ADHD.
The team concluded, “Our systematic review and meta-analysis of observational studies indicates that the heightened risks of ADHD and ASD observed in children gestationally exposed to antipsychotics appear to be attributable to maternal characteristics, rather than having a causal relation to the antipsychotic itself.”
Most previous studies of suicide and self-harm risk among persons with ADHD have focused on adolescents and adults. They’ve also tended to be cross-sectional, analyzing data from a population at a specific point in time.
An Australian study team took a different approach, conducting a before-and-after study through the birth cohort of the Longitudinal Study of Australian Children (LSAC), comprising 5,107 children who have been followed up every two years since birth.
The diagnosis of ADHD was based on parents reporting that their child had received a diagnosis of ADHD at or before age ten.
Suicide and self-harm were defined as children’s self-report at age 14 of any thought or attempt of suicide and self-harm respectively over the past year.
The team adjusted for the following confounders: socioeconomic status, birth weight, ADHD medication history, maternal education level, maternal age at birth, experience in bullying victimization at age 12, and depression score based on Short Mood and Feelings Questionnaire (SMFQ).
Of the 5,107 participants, 3,696 had all the valid data required for analysis and were included in the final cohort. Of these, 3.6% were diagnosed with ADHD by age 10.
With a diagnosis of ADHD at age 10 and all other factors held constant:
Both depression and exposure to bullying were statistically significant mediators for the relationship. Nevertheless, depression and exposure to bullying each accounted for well under 10% of the overall effect.
Neither socioeconomic status nor maternal factors had any significant mediating effect on outcomes.
The authors concluded, “This study provides compelling evidence that children diagnosed with ADHD at the age of 10 years face significantly elevated risks of experiencing suicidal thoughts, planning, or attempts, as well as self-harm, by the age of 14 years, which underscores the critical importance of recognizing and addressing these heightened risks in children with ADHD.”
_logo%201.svg)
